May 19, 2020
NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment
Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Free Daily News
- Hospital safety grades show progress in reducing medical errors, infections
- Analysis: Overuse of back surgeries costs Medicare $2 billion, risks patient safety
- AI-powered surgical robot learns by watching
- AHA's Congressional "wish list" calls for financial relief, patient access, workforce protections
- Out-of-hospital cardiac arrest survival rates lag pre-pandemic levels, racial disparities persist
- Honoring the OR Manager Award winners this Perioperative Nurses Week
- Study: Demand for anesthesiologists rises sharply, driven by job market, regional variations
- Joint Commission Sentinel Event Alert details environmental disaster preparation
- ACS recognizes 77 hospitals for excellence in surgical outcomes
- Color-changing gel could enhance cataract surgery safety, efficiency
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement